Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is adapting its existing tools, designed for emerging respiratory pathogens, for the current outbreak of global significance. This is an international resource for facilitating the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with novel coronavirus.

Coronavirus close-up © National Institute of Allergy and Infectious Diseases (NIAID)

On 31st  December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown cause in Wuhan City, Hubei Province of the People’s Republic of China. The etiologic agent has been identified as a novel Betacoronavirus (2019-nCoV). Cases of infection with 2019-nCoV have been detected in travellers to Thailand, Japan, Korea and the US, and, on 19th January, the case numbers reported from China increased significantly. The emerging data suggest that person-to-person transmission is occurring, and there is a threat of further escalation and international spread.

In the past, clinical data on emerging infections have not been collected, standardised, or shared quickly enough to inform the outbreak response and patient care. ISARIC – whose Global Support Centre is hosted by the University of Oxford - has a long-standing programme of work on emerging respiratory pathogens which is being adapted for the current outbreak. 

  • Standardised clinical data collection and curation
    Based on a pre-existing ISARIC global observational study of severe acute respiratory infections (SPRINT-SARI), ISARIC has adapted the case record form (CRF) to assist with the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with nCoV. This CRF will be made available via WHO and other open-access sources as a global resource for public health purposes. A data management platform will be offered by the ISARIC Global Support Centre.
  • Clinical observational studies
    Based on a pre-existing ISARIC Clinical Characterisation Protocol, the federation is making available an observational clinical protocol (with associated patient information leaflets and consent form) that allows data collection that is harmonised with standardised clinical data collection and curation, and sequential biological sampling for research purposes. A data management platform will be offered by the ISARIC Global Support Centre.
  • Clinical trials of therapeutics
    The federation is working with ISARIC partners and with WHO on developing and implementing clinical trials for therapeutics for 2019-nCoV. These are randomised controlled trial protocols.

This work is being supported by a wide range of ISARIC partners and the ISARIC Global Support Centre, as a global resource. Professor Peter Horby, Executive Director of ISARIC, said:

Patients are at the heart of every outbreak. Our work gives local teams the tools they need to react quickly and effectively to this outbreak, doing vital research to advance understanding and improve patient care.

ISARIC stands by the Principles of Data Sharing in public health emergencies as defined through work led by the funders consortium GloPID-R. As such, ISARIC commits to underpinning implementation of timely data sharing. ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur. ISARIC is funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden